Deutsche Bank AG bought a new position in Kenvue Inc. (NYSE:KVUE - Free Report) during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm bought 7,920,744 shares of the company's stock, valued at approximately $151,365,000. Deutsche Bank AG owned 0.41% of Kenvue at the end of the most recent quarter.
Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Perigon Wealth Management LLC purchased a new stake in Kenvue during the second quarter valued at about $635,000. Commerzbank Aktiengesellschaft FI purchased a new position in shares of Kenvue in the 2nd quarter worth about $1,407,000. Principle Wealth Partners LLC purchased a new position in shares of Kenvue in the 2nd quarter worth about $367,000. Mitsubishi UFJ Asset Management Co. Ltd. acquired a new position in shares of Kenvue in the 2nd quarter valued at about $96,092,000. Finally, OneDigital Investment Advisors LLC acquired a new position in shares of Kenvue in the 2nd quarter valued at about $349,000. Institutional investors and hedge funds own 97.64% of the company's stock.
Kenvue Price Performance
KVUE opened at $19.16 on Thursday. The company has a fifty day simple moving average of $19.02 and a 200 day simple moving average of $18.18. The firm has a market cap of $36.80 billion, a price-to-earnings ratio of 22.02, a PEG ratio of 1.35 and a beta of 0.47. Kenvue Inc. has a twelve month low of $14.02 and a twelve month high of $21.84. The company has a current ratio of 1.01, a quick ratio of 0.71 and a debt-to-equity ratio of 0.67.
Kenvue (NYSE:KVUE - Get Free Report) last released its quarterly earnings results on Thursday, August 6th. The company reported $0.31 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.32 by ($0.01). Kenvue had a return on equity of 21.22% and a net margin of 10.76%.The firm had revenue of $3.96 billion for the quarter, compared to analysts' expectations of $3.97 billion. During the same period last year, the firm earned $0.29 EPS. The business's quarterly revenue was up 3.0% on a year-over-year basis. Equities research analysts expect that Kenvue Inc. will post 1.14 EPS for the current fiscal year.
Kenvue Increases Dividend
The firm also recently announced a quarterly dividend, which will be paid on Wednesday, August 26th. Stockholders of record on Wednesday, August 12th will be given a dividend of $0.21 per share. The ex-dividend date of this dividend is Wednesday, August 12th. This is a positive change from Kenvue's previous quarterly dividend of $0.21. This represents a $0.84 dividend on an annualized basis and a dividend yield of 4.4%. Kenvue's dividend payout ratio is presently 96.55%.
Analysts Set New Price Targets
A number of analysts recently issued reports on KVUE shares. Wall Street Zen downgraded shares of Kenvue from a "buy" rating to a "hold" rating in a research report on Saturday, August 8th. Zacks Research lowered shares of Kenvue from a "strong-buy" rating to a "hold" rating in a report on Tuesday, July 7th. Barclays lifted their price target on shares of Kenvue from $18.00 to $19.00 and gave the company an "equal weight" rating in a research report on Tuesday, July 21st. UBS Group decreased their price objective on shares of Kenvue from $20.00 to $19.00 and set a "neutral" rating for the company in a research note on Tuesday, August 11th. Finally, Weiss Ratings raised shares of Kenvue from a "hold (c-)" rating to a "hold (c)" rating in a research report on Monday, June 15th. Three research analysts have rated the stock with a Buy rating and twelve have issued a Hold rating to the stock. Based on data from MarketBeat.com, Kenvue has a consensus rating of "Hold" and a consensus price target of $19.27.
View Our Latest Analysis on Kenvue
Kenvue Profile
(
Free Report)
Kenvue is a consumer health company that was established as a standalone, publicly traded business after separating from Johnson & Johnson. Listed on the New York Stock Exchange under the symbol KVUE, Kenvue focuses on the development, manufacture, marketing and distribution of consumer health and personal care products across a range of categories including skin and beauty care, baby care, oral care, wound care and over‑the‑counter medicines.
The company owns and markets a portfolio of widely recognized consumer brands, including names familiar to global shoppers across retail and pharmacy channels.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider Kenvue, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Kenvue wasn't on the list.
While Kenvue currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
